130 related articles for article (PubMed ID: 38880494)
1. A multicenter, double-blind, randomized, parallel-group, active-controlled, phase 3 clinical trial to compare the effectiveness and safety of two botulinum toxin type A formulations for improving moderate to severe glabellar wrinkles in Asians.
Choi SY; Koh YG; Lee YW; Son HS; Yoon YN; Kim G; Won C; Cho H; Son JS; Kim EK; Kim BJ
J Dermatolog Treat; 2024 Dec; 35(1):2359511. PubMed ID: 38880494
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines.
Kim JE; Song EJ; Choi GS; Lew BL; Sim WY; Kang H
Plast Reconstr Surg; 2015 Mar; 135(3):732-741. PubMed ID: 25719692
[TBL] [Abstract][Full Text] [Related]
3. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.
Carruthers A; Carruthers J; Said S
Dermatol Surg; 2005 Apr; 31(4):414-22; discussion 422. PubMed ID: 15871316
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
[TBL] [Abstract][Full Text] [Related]
5. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study.
Won CH; Kim HK; Kim BJ; Kang H; Hong JP; Lee SY; Kim CS
Int J Dermatol; 2015 Feb; 54(2):227-34. PubMed ID: 25311357
[TBL] [Abstract][Full Text] [Related]
6. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety.
Brandt F; Swanson N; Baumann L; Huber B
Dermatol Surg; 2009 Dec; 35(12):1893-901. PubMed ID: 19549186
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study.
Won CH; Lee HM; Lee WS; Kang H; Kim BJ; Kim WS; Lee JH; Lee DH; Huh CH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):171-8. PubMed ID: 23301821
[TBL] [Abstract][Full Text] [Related]
8. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI.
Grimes PE; Shabazz D
Dermatol Surg; 2009 Mar; 35(3):429-35; discussion 435-6. PubMed ID: 19250310
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids.
Beer KR
Dermatol Surg; 2006 Feb; 32(2):184-97. PubMed ID: 16442037
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of a New Botulinum Toxin (HU-014) Versus Existing Onabotulinumtoxin A in Subjects With Moderate to Severe Glabellar Lines.
Yoo KH; Lee YW; Lee JS; Kwon SH; Huh CH; Kim BJ
Dermatol Surg; 2021 Mar; 47(3):e91-e96. PubMed ID: 33481449
[TBL] [Abstract][Full Text] [Related]
12. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).
Bertucci V; Solish N; Kaufman-Janette J; Yoelin S; Shamban A; Schlessinger J; Snyder D; Gallagher C; Liu Y; Shears G; Rubio RG
J Am Acad Dermatol; 2020 Apr; 82(4):838-845. PubMed ID: 31791824
[TBL] [Abstract][Full Text] [Related]
13. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study.
Alimohammadi M; Andersson M; Punga AR
Acta Derm Venereol; 2014 Jan; 94(1):32-7. PubMed ID: 23975053
[TBL] [Abstract][Full Text] [Related]
14. A Phase III Clinical Study of the Efficacy and Safety of Botulinum Toxin Type A (MASPORT) with DYSPORT for the Treatment of Glabellar Lines.
Hedayat K; Ehsani AH
Aesthetic Plast Surg; 2024 Feb; 48(3):324-332. PubMed ID: 38233684
[TBL] [Abstract][Full Text] [Related]
15. Does Increasing the Dose of Abobotulinumtoxina Impact the Duration of Effectiveness for the Treatment of Moderate to Severe Glabellar Lines?
Joseph JH; Eaton LL; Robinson J; Pontius A; Williams EF
J Drugs Dermatol; 2016 Dec; 15(12):1544-1549. PubMed ID: 29106437
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials.
Li X; Sui C; Xia X; Chen X
Aesthetic Plast Surg; 2023 Feb; 47(1):365-377. PubMed ID: 36097079
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects.
Kane MA
Aesthetic Plast Surg; 2008 Nov; 32(6):933-5. PubMed ID: 18685887
[No Abstract] [Full Text] [Related]
18. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies.
Beer KR; Shamban AT; Avelar RL; Gross JE; Jonker A
Dermatol Surg; 2019 Nov; 45(11):1381-1393. PubMed ID: 30893162
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
Rzany BJ; Ascher B; Avelar RL; Bergdahl J; Bertucci V; Bodokh I; Carruthers JA; Cartier H; Delmar H; Denfeld R; Gross JE; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Sattler G; Sebastian M; Solish N; Swift A; Trévidic P
Aesthet Surg J; 2020 Mar; 40(4):413-429. PubMed ID: 30951166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
